Reports
Impact of breast cancer generics in Europe
Breast cancer generics can increase patient adherence and reduce healthcare budgets for European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).
Impact of hypertension generics in Europe
A report by the Germany-based Institute for Healthcare and Social Research (IGES) released in November 2015 found that generics of drugs to treat high blood pressure can increase patient adherence and reduce healthcare budgets for European countries.
Impact of generics on European budgets
A report by the Germany-based Institute for Healthcare and Social Research (IGES) released on 16 November 2015 found that generics could contribute to reducing healthcare budgets for European countries.
Generics market share in Europe
Generics make a major contribution to the European drug supply, according to a report by the by Germany-based Institute for Healthcare and Social Research (IGES).
Generics reduce costs and increase access
Generics reduce costs for both patients and payers and increase patient’s access to medicines, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).
Generics savings continue to climb in the US
Generics manufacturers have joined to celebrate the latest data from the Generic Drug Savings in the US report. According to the report, the US healthcare system saved a record US$254 billion in 2014 from generics, or US$1.68 trillion between 2005 and 2014.
Pivotal clinical trials for trastuzumab biosimilars
Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.
Pivotal clinical trials for rituximab biosimilars
Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.
German physicians not pressured to switch to biosimilar infliximab
Rheumatologists and gastroenterologists in Germany are not being put under pressure to switch patients from Remicade (infliximab) to biosimilar infliximab, according to a new report from research and advisory firm Decision Resources.
Pivotal clinical trials for bevacizumab biosimilars
Biosimilars of Roche’s Avastin (bevacizumab), a humanized monoclonal antibody, are currently under development.
